This trial is a multi-center, open label, randomized controlled, non-inferiority phase III
trial evaluating the safety and efficacy of a 3 g oral dose of zoliflodacin compared to a
combination of a single intra-muscular 500 mg dose of ceftriaxone and a single 1 g oral dose
of azithromycin for the treatment of uncomplicated gonorrhoea.
Phase:
Phase 3
Details
Lead Sponsor:
Global Antibiotics Research and Development Partnership